Endocrine treatment, with or without radiotherapy, in locally advanced prostate cancer (SPCG-7/SFUO-3): an open randomised phase III trial.
about
Evolving Paradigm of Radiotherapy for High-Risk Prostate Cancer: Current Consensus and Continuing ControversiesAddition of docetaxel or bisphosphonates to standard of care in men with localised or metastatic, hormone-sensitive prostate cancer: a systematic review and meta-analyses of aggregate data.Hormone therapy in combination with radiotherapy in the treatment of prostate cancer: why and in which group of patients?Current clinical challenges in prostate cancerProstate radiotherapy for men with metastatic disease: a new comparison in the Systemic Therapy in Advancing or Metastatic Prostate Cancer: Evaluation of Drug Efficacy (STAMPEDE) trialManagement of low (favourable)-risk prostate cancerA comprehensive review of contemporary role of local treatment of the primary tumor and/or the metastases in metastatic prostate cancerProstate cancer: ESMO Consensus Conference Guidelines 2012PET imaging of prostate-specific membrane antigen in prostate cancer: current state of the art and future challengesEfficacy and Safety of Combined Androgen Deprivation Therapy (ADT) and Docetaxel Compared with ADT Alone for Metastatic Hormone-Naive Prostate Cancer: A Systematic Review and Meta-AnalysisAdvances in hormonal therapies for hormone naïve and castration-resistant prostate cancers with or without previous chemotherapyPSA nadir as a predictive factor for biochemical disease-free survival and overall survival following whole-gland salvage HIFU following radiotherapy failure.Celecoxib plus hormone therapy versus hormone therapy alone for hormone-sensitive prostate cancer: first results from the STAMPEDE multiarm, multistage, randomised controlled trial.Failure-Free Survival and Radiotherapy in Patients With Newly Diagnosed Nonmetastatic Prostate Cancer: Data From Patients in the Control Arm of the STAMPEDE Trial.Prospective assessment of urinary, gastrointestinal and sexual symptoms before, during and after image-guided volumetric modulated arc therapy for prostate cancer.High-dose-rate brachytherapy and hypofractionated external beam radiotherapy combined with long-term hormonal therapy for high-risk and very high-risk prostate cancer: outcomes after 5-year follow-upAdjuvant medical therapy for prostate cancer.Primary radiotherapy vs conservative management for localized prostate cancer--a population-based study.Clinical pharmacology and regulatory consequences of GnRH analogues in prostate cancerRadiation therapy in prostate cancer: a risk-adapted strategy.Androgen deprivation therapy for prostate cancer-review of indications in 2010Longitudinal magnetic resonance imaging-based assessment of vascular changes and radiation response in androgen-sensitive prostate carcinoma xenografts under androgen-exposed and androgen-deprived conditionsTri-Modality therapy with I-125 brachytherapy, external beam radiation therapy, and short- or long-term hormone therapy for high-risk localized prostate cancer (TRIP): study protocol for a phase III, multicenter, randomized, controlled trial.Contemporary role of androgen deprivation therapy for prostate cancerVascular responses to radiotherapy and androgen-deprivation therapy in experimental prostate cancer.Comparative risk-adjusted mortality outcomes after primary surgery, radiotherapy, or androgen-deprivation therapy for localized prostate cancer.Radiotherapy combined with hormonal therapy in prostate cancer: the state of the art.(18)F-FDG-PET/CT and (18)F-NaF-PET/CT in men with castrate-resistant prostate cancer.Hormone therapy in the management of prostate cancer: evidence-based approachesAndrogen withdrawal fails to induce detectable tissue hypoxia in the rat prostateEffectiveness of androgen-deprivation therapy and radiotherapy for older men with locally advanced prostate cancer.Long-term survival after radical prostatectomy versus external-beam radiotherapy for patients with high-risk prostate cancerTrends and outcome from radical therapy for primary non-metastatic prostate cancer in a UK population.Management of high-risk localized prostate cancer.Combined androgen deprivation therapy and radiation therapy for locally advanced prostate cancer: a randomised, phase 3 trial.The impact of increasing dose on overall survival in prostate cancer.Bias in estimating the causal hazard ratio when using two-stage instrumental variable methods.Final Report of the Intergroup Randomized Study of Combined Androgen-Deprivation Therapy Plus Radiotherapy Versus Androgen-Deprivation Therapy Alone in Locally Advanced Prostate CancerSingle blind randomized phase III trial to investigate the benefit of a focal lesion ablative microboost in prostate cancer (FLAME-trial): study protocol for a randomized controlled trial.Impact of the duration of hormonal therapy following radiotherapy for localized prostate cancer.
P2860
Q26744606-754704B4-FDB8-4ADD-BAA0-834A8B36F0FCQ26771537-9F49DDF4-9C2D-45A4-8818-8809329F18FCQ26801132-20FD3D70-BF8A-40AD-A49A-B4031FE07C19Q26866036-F7261E98-4D12-48BA-8A0D-1EB6973D43A1Q26866565-77205E4B-5D36-4090-B08B-CDF77CC56FF4Q26996501-F8D32BAA-7910-49C9-BCAA-9CCD375BE037Q27000180-4E41FDF1-EC08-4DE3-AE36-249CA1DF47B1Q27022847-C3D26E8B-3A5E-4F38-B590-81C16DA51D1AQ28067404-BC8DCFBA-7F65-4D2E-9771-09082AD528A0Q28550301-B7C4E63C-B09C-4488-97BC-F84A1F773586Q28829239-F325C12F-BC81-413F-86D8-24828A493B15Q30365461-C0578196-9BFE-42E1-BF90-4ACDAC939DDEQ30521133-28C83FFD-9296-48C3-8427-402DA8B31016Q31028126-F496ACE7-2CCA-4E77-9F3B-06BA9AF9E8A6Q33461489-06E6B21A-429D-4F99-9A02-C13A24F1981DQ33582598-3A6F6A89-D659-4073-92BD-809457859819Q33758771-0D68AC86-8546-402B-95F3-CA281329AB58Q33919551-8FCB0F8B-B084-4128-A93D-E0D4677903C6Q34104391-0E975599-A28E-4C34-AA25-7D0290946C05Q34111590-44AD74E9-E664-4440-8468-19003EE2FDC6Q34111603-DC521EB6-B8D6-4B7E-8E67-A6DBC7BD397DQ34177229-6ED21655-E7BA-4D06-8310-F7CE1BFE8DC9Q34206798-51C9188E-21DC-4073-A123-EEE21326DBFFQ34211155-636C1480-00A0-4658-AC90-56AF4404B8BFQ34279214-773711EC-EDB8-464F-8D0B-ADAEC46BAB3CQ34288796-83B38F0A-F062-4BF2-9E46-56F2B969BA97Q34417815-D48B1523-9B0F-443B-860E-E6B83F3E9D9CQ34987693-BF80A50E-C91A-4588-8B16-27C352899EA2Q35076432-BFC6AEFF-0186-4DAA-892A-08FE19C5687DQ35095977-9C4F438B-3014-488A-ADD0-6279B2BE9890Q35102488-DB03CC42-170E-4C0E-A8C3-76C8BA08A721Q35115736-39ABE2C9-D88C-4620-90CF-3EC3A63328D6Q35151890-16FC836B-FC7E-45B3-AFB8-7FED835AB59BQ35503645-0F708FEE-1160-4268-97E6-152770CDF0A8Q35627417-FB2236B4-BBFB-4F5F-A911-5A39D77EBC0FQ35663315-D36C79DB-68FC-4880-AE0E-A76BF04BE5D7Q35684054-E917D29D-87A2-435D-874C-75EF0DB1A2F3Q35771166-843C54EB-1733-414B-96BD-28D9E0A71709Q35777339-ABF380B5-F4D3-49CA-956D-BA5EE847FB52Q35803832-1D97D976-0618-4CBB-B655-7E23E214FE64
P2860
Endocrine treatment, with or without radiotherapy, in locally advanced prostate cancer (SPCG-7/SFUO-3): an open randomised phase III trial.
description
2008 nî lūn-bûn
@nan
2008年の論文
@ja
2008年論文
@yue
2008年論文
@zh-hant
2008年論文
@zh-hk
2008年論文
@zh-mo
2008年論文
@zh-tw
2008年论文
@wuu
2008年论文
@zh
2008年论文
@zh-cn
name
Endocrine treatment, with or w ...... en randomised phase III trial.
@en
Endocrine treatment, with or w ...... en randomised phase III trial.
@nl
type
label
Endocrine treatment, with or w ...... en randomised phase III trial.
@en
Endocrine treatment, with or w ...... en randomised phase III trial.
@nl
prefLabel
Endocrine treatment, with or w ...... en randomised phase III trial.
@en
Endocrine treatment, with or w ...... en randomised phase III trial.
@nl
P2093
P1433
P1476
Endocrine treatment, with or w ...... en randomised phase III trial.
@en
P2093
Anders Angelsen
Anders Widmark
Arne Solberg
Fredrik Wiklund
Ilker Tasdemir
Jan-Erik Damber
Jo-Asmund Lund
Morten Hoyer
Olbjørn Klepp
Per Fransson
P304
P356
10.1016/S0140-6736(08)61815-2
P407
P577
2008-12-16T00:00:00Z